FeRx Inc. Announces New VicePresident.

Business Editors & Health/Medical Writers

BIOWIRE2K

SAN DIEGO--(BW HealthWire)--April 17, 2000

FeRx Inc., a privately held drug delivery company, today announced that W. Todd Myers, C.P.A., has joined the company as vice president, finance and business development.

"We are thrilled to have Todd join the company as he brings significant financial expertise, especially in the area of biotechnology," Dr. Johnson said. "His experience with CombiChem will be a tremendous asset as we continue to execute our business plan."

Most recently, Myers was the director of finance for CombiChem Inc., a computational drug discovery company, where he managed the growth of the organization from 40 to 100 employees. He guided CombiChem through its initial public offering and successfully completed the sale of the company to DuPont Pharmaceuticals in November 1999. Myers has also held senior financial and accounting positions at Premier Inc., a national consortium of health care providers, and with Ernst & Young LLP. He received his Bachelors degree from the University of Illinois.

FeRx Inc. is a privately held drug delivery company focused on the development and commercialization of its proprietary Magnetic Targeted Carriers (MTC) technology. FeRx's lead compound, MTC-Doxorubicin, is in Phase I/II clinical trials for primary liver cancer. Clinical trials investigating the use of MTC to deliver additional drugs in other solid tumor indications are planned for later this year. While the company is focusing on cancer therapy applications in its initial clinical trials, the MTC drug delivery technology will continue to be investigated for site specific delivery and sustained release of various classes of pharmaceutical agents in other therapeutic areas.

For additional company background and information about employment opportunities, visit the FeRx Inc. Web site at: www.FeRx.com.

Editor's Note: Jpeg photo available upon request.